Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th
Back

Chemesis International Inc. Closes $25 Million Equity Financing with Alumina Partners, LLC.

Aug 7, 2018 • 3:09 PM EDT
Canada Stocks (10).png
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Chemesis International Inc. (CSE: CSI), is pleased to announce the Company has closed a draw-down equity financing of up to $25,000,000 CDN, with Alumina Partners, LLC, a New York-based private equity firm that has made substantial investments in the cannabis space.

The purpose of the agreement is to allow Chemesis to continue its growth strategy with complete financial flexibility and freedom. The financing is at the sole discretion of Chemesis, allowing for the ability to access funds when necessary. This strategy allows Chemesis to protect shareholder value while growing to meet demands in California and around the globe.

“We are very enthusiastic to be entering into such a major agreement, allowing us to be an aggressive first mover in California. This agreement will allow Chemesis major financial flexibility in its operations,” said CEO, Edgar Montero. “Such major investments are rare in the early stages and we are excited to receive such a significant commitment from Alumina Partners, LLC.  This serves as meaningful validation of our business plan and growth strategy.”

“As the regulated cannabis marketplace continues to expand and evolve globally, product differentiation has proven invaluable to the boldest ventures in the space,” added Adi Nahmani, Managing Member of Alumina Partners, LLC. “We are pleased to help support Chemesis as they reinvest to open a new chapter of growth in the largest market in North America.”

The agreement details the purchase of up to $25,000,000 of units of the Company (the “Units”), consisting of one common share (the “Share”) and one common share purchase warrant (the “Warrants”), at discounts ranging from 15% to 25% of the market price of the Shares, with each Private Placement Offering occurring exclusively at the option of the Company, throughout the 24 month term of the agreement. The exercise price of the Warrants will be at a 50% premium over the market price of the Shares. There are no upfront fees or interest associated with the use of this financing.

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated leader in the cannabis industry, currently operating within California.

Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution, and retail. Chemesis has a facility in California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods, to provide consumers with quality cannabis products.

Chemesis will add shareholder value by exploring opportunities in other emerging markets while consistently delivering quality product to its consumers from seed to sale.

ON BEHALF OF THE BOARD OF DIRECTORS

Edgar Montero

CEO and Director

INVESTOR RELATIONS:

ir@chemesis.com

www.chemesis.com

1 (604) 398-3378

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

 

The CSE has not reviewed, approved or disapproved the content of this press release

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Mushroomstocks.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link